Clin2
NCT07016113Possibly a fitNot yet recruiting

Latanoprost gel for vitiligo in teens

Vitiligo - Macular Depigmentation

Part of Skin clinical trials.

This trial tests a gel called latanoprost for teens with stable vitiligo. It looks at whether the gel helps bring back color to white patches on the skin.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
10 people
Ages
10 years to 17 years
Study type
Interventional

Who can take part

  • You have non-segmental vitiligo (white patches on both sides of your body).
  • Your vitiligo has been stable (no new patches or growth) for at least 6 months.
  • You are between 10 and 17 years old.
  • Your vitiligo covers less than 10% of your body.
  • You have at least two patches that are similar in size (1 to 4 square centimeters), one on each side of your body, and not on palms, soles, or genitals.
  • You have not used certain creams, pills, or light therapy for vitiligo for at least 2 weeks (or 4 weeks for some) before starting.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06880042Enrolling by invitation· Early Phase 1
Narrowband UVB light therapy with tacrolimus or calcipotriol for vitiligo

This study compares two treatments for vitiligo: narrowband UVB light therapy combined with either tacrolimus ointment or calcipotriol ointment. It aims to see which combination works better and is safer for people with stable, limited vitiligo.

Lahore, Punjab Province
NCT07509242Not yet recruiting· Phase 2/Phase 3
Secretome gel plus light therapy for stable vitiligo

This trial tests a new gel made from stem-cell substances (secretome) given with narrow-band UVB light therapy for stable non-segmental vitiligo. It compares two ways of applying the gel to see which works better.

Tangerang, Banten
NCT07667569Not yet recruiting· Phase 2
A study of ACT-777991 for adults with non-segmental vitiligo

This trial tests a new oral medication called ACT-777991 to see if it is safe and can help repigment skin in adults with non-segmental vitiligo (the most common type that affects both sides of the body). Participants must have at least a certain amount of pigment loss on the face and total body, and agree not to use other vitiligo treatments during the study.

NCT07673640Not yet recruiting
Ruxolitinib cream with steroids for active vitiligo on face

This trial tests a cream (ruxolitinib) combined with corticosteroid treatment for people with active, non-segmental vitiligo that affects the face. It aims to see how well this combination works in real-world settings.

Huai'an, Jiangsu
NCT06548360Recruiting· Phase 3
Testing ruxolitinib cream for children with vitiligo

This study tests a cream called ruxolitinib for children with nonsegmental vitiligo. It aims to see if the cream can safely help restore skin color in affected areas.

Birmingham, Alabama
NCT07682506Recruiting· Phase 3
Testing a new vitiligo ointment for face and body patches

This trial tests an ointment called MH004 to see if it helps repigment white patches in people with non-segmental vitiligo (the most common type). It focuses on patches on the face and body.

Beijing, Beijing Municipality

Hear when a new Vitiligo - Macular Depigmentation trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.